A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Pfizer Plans to Submit EUA Application for its COVID-19 Vaccine in Late November


Pfizer CEO Albert Bourla, DVM, PhD, posted a letter on the company’s website noting that the Pfizer/BioNTech COVID-19 vaccine should be ready to apply for the United States Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) by the third week of November. The FDA requires at least 2 months of safety data on 50% of clinical trial participants before granting an EUA for any COVID-19 vaccine.

The Pfizer vaccine is based on synthetic messenger RNA (mRNA), a new technology that helps the body’s own immune system identify and then combat the novel coronavirus by copying its surface. Read more here.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy